Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study

Dinesh Khanna, Philip J. Clements, Daniel E. Furst, Yun Chon, Robert Elashoff, Michael D. Roth, Mildred G. Sterz, Joannie Chung, John D. FitzGerald, James R. Seibold, John Varga, Arthur Theodore, Fredrick Wigley, Richard M. Silver, Virginia D. Steen, Maureen D. Mayes, M. Kari Connolly, Barri J. Fessler, Naomi F. Rothfield, Kamal MubarakJerry Molitor, Donald P. Tashkin

Research output: Contribution to journalArticle

Abstract

Objective. To determine whether baseline self-assessment measures of health status and physiologic indices of disease severity in alveolitis-positive patients with systemic sclerosis (SSc) correlate with the severity of their dyspnea, and to quantify functional impairment in patients with scleroderma lung disease and compare it with that in patients with chronic obstructive pulmonary disease (COPD). Methods. SSc patients (n = 138) with diffuse (n = 81) or limited (n = 57) cutaneous disease and active alveolitis (determined by bronchoalveolar lavage and/or high-resolution computed tomography) who participated in the National Heart, Lung, and Blood Institute-sponsored, multicenter, parallel-group, double-blind, randomized, placebo-controlled trial of oral cyclophosphamide for treatment of SSc-associated interstitial lung disease were evaluated. Pearson's univariate correlations were determined between the Short Form 36 (SF-36) physical component summary (PCS) and mental component summary (MCS) scales, functional questionnaires, and physiologic parameters of breathing (forced vital capacity [FVC] and single-breath diffusing capacity for carbon monoxide [DLCO]). Student's t-test was used to compare subgroups. Scores from 2 instruments for self-assessment of breathlessness, Mahler's baseline dyspnea index (BDI) and a visual analog scale (VAS) for breathing, were divided at the median. Values for the DLCO and FVC (% predicted) were divided based on the American Thoracic Society guidelines for mild (>70% of predicted), moderate (50-70% of predicted), and severe (

Original languageEnglish (US)
Pages (from-to)592-600
Number of pages9
JournalArthritis and Rheumatism
Volume52
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Aptitude
Systemic Scleroderma
Carbon Monoxide
Dyspnea
Quality of Life
Lung
Vital Capacity
Respiration
Health Status Indicators
National Heart, Lung, and Blood Institute (U.S.)
Interstitial Lung Diseases
Bronchoalveolar Lavage
Visual Analog Scale
Skin Diseases
Cyclophosphamide
Chronic Obstructive Pulmonary Disease
Lung Diseases
Randomized Controlled Trials
Tomography
Placebos

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis : Results from the scleroderma lung study. / Khanna, Dinesh; Clements, Philip J.; Furst, Daniel E.; Chon, Yun; Elashoff, Robert; Roth, Michael D.; Sterz, Mildred G.; Chung, Joannie; FitzGerald, John D.; Seibold, James R.; Varga, John; Theodore, Arthur; Wigley, Fredrick; Silver, Richard M.; Steen, Virginia D.; Mayes, Maureen D.; Connolly, M. Kari; Fessler, Barri J.; Rothfield, Naomi F.; Mubarak, Kamal; Molitor, Jerry; Tashkin, Donald P.

In: Arthritis and Rheumatism, Vol. 52, No. 2, 02.2005, p. 592-600.

Research output: Contribution to journalArticle

Khanna, D, Clements, PJ, Furst, DE, Chon, Y, Elashoff, R, Roth, MD, Sterz, MG, Chung, J, FitzGerald, JD, Seibold, JR, Varga, J, Theodore, A, Wigley, F, Silver, RM, Steen, VD, Mayes, MD, Connolly, MK, Fessler, BJ, Rothfield, NF, Mubarak, K, Molitor, J & Tashkin, DP 2005, 'Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study', Arthritis and Rheumatism, vol. 52, no. 2, pp. 592-600. https://doi.org/10.1002/art.20787
Khanna, Dinesh ; Clements, Philip J. ; Furst, Daniel E. ; Chon, Yun ; Elashoff, Robert ; Roth, Michael D. ; Sterz, Mildred G. ; Chung, Joannie ; FitzGerald, John D. ; Seibold, James R. ; Varga, John ; Theodore, Arthur ; Wigley, Fredrick ; Silver, Richard M. ; Steen, Virginia D. ; Mayes, Maureen D. ; Connolly, M. Kari ; Fessler, Barri J. ; Rothfield, Naomi F. ; Mubarak, Kamal ; Molitor, Jerry ; Tashkin, Donald P. / Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis : Results from the scleroderma lung study. In: Arthritis and Rheumatism. 2005 ; Vol. 52, No. 2. pp. 592-600.
@article{57b26bb1c818466c8baf1d5e4d4b43cb,
title = "Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study",
abstract = "Objective. To determine whether baseline self-assessment measures of health status and physiologic indices of disease severity in alveolitis-positive patients with systemic sclerosis (SSc) correlate with the severity of their dyspnea, and to quantify functional impairment in patients with scleroderma lung disease and compare it with that in patients with chronic obstructive pulmonary disease (COPD). Methods. SSc patients (n = 138) with diffuse (n = 81) or limited (n = 57) cutaneous disease and active alveolitis (determined by bronchoalveolar lavage and/or high-resolution computed tomography) who participated in the National Heart, Lung, and Blood Institute-sponsored, multicenter, parallel-group, double-blind, randomized, placebo-controlled trial of oral cyclophosphamide for treatment of SSc-associated interstitial lung disease were evaluated. Pearson's univariate correlations were determined between the Short Form 36 (SF-36) physical component summary (PCS) and mental component summary (MCS) scales, functional questionnaires, and physiologic parameters of breathing (forced vital capacity [FVC] and single-breath diffusing capacity for carbon monoxide [DLCO]). Student's t-test was used to compare subgroups. Scores from 2 instruments for self-assessment of breathlessness, Mahler's baseline dyspnea index (BDI) and a visual analog scale (VAS) for breathing, were divided at the median. Values for the DLCO and FVC ({\%} predicted) were divided based on the American Thoracic Society guidelines for mild (>70{\%} of predicted), moderate (50-70{\%} of predicted), and severe (",
author = "Dinesh Khanna and Clements, {Philip J.} and Furst, {Daniel E.} and Yun Chon and Robert Elashoff and Roth, {Michael D.} and Sterz, {Mildred G.} and Joannie Chung and FitzGerald, {John D.} and Seibold, {James R.} and John Varga and Arthur Theodore and Fredrick Wigley and Silver, {Richard M.} and Steen, {Virginia D.} and Mayes, {Maureen D.} and Connolly, {M. Kari} and Fessler, {Barri J.} and Rothfield, {Naomi F.} and Kamal Mubarak and Jerry Molitor and Tashkin, {Donald P.}",
year = "2005",
month = "2",
doi = "10.1002/art.20787",
language = "English (US)",
volume = "52",
pages = "592--600",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis

T2 - Results from the scleroderma lung study

AU - Khanna, Dinesh

AU - Clements, Philip J.

AU - Furst, Daniel E.

AU - Chon, Yun

AU - Elashoff, Robert

AU - Roth, Michael D.

AU - Sterz, Mildred G.

AU - Chung, Joannie

AU - FitzGerald, John D.

AU - Seibold, James R.

AU - Varga, John

AU - Theodore, Arthur

AU - Wigley, Fredrick

AU - Silver, Richard M.

AU - Steen, Virginia D.

AU - Mayes, Maureen D.

AU - Connolly, M. Kari

AU - Fessler, Barri J.

AU - Rothfield, Naomi F.

AU - Mubarak, Kamal

AU - Molitor, Jerry

AU - Tashkin, Donald P.

PY - 2005/2

Y1 - 2005/2

N2 - Objective. To determine whether baseline self-assessment measures of health status and physiologic indices of disease severity in alveolitis-positive patients with systemic sclerosis (SSc) correlate with the severity of their dyspnea, and to quantify functional impairment in patients with scleroderma lung disease and compare it with that in patients with chronic obstructive pulmonary disease (COPD). Methods. SSc patients (n = 138) with diffuse (n = 81) or limited (n = 57) cutaneous disease and active alveolitis (determined by bronchoalveolar lavage and/or high-resolution computed tomography) who participated in the National Heart, Lung, and Blood Institute-sponsored, multicenter, parallel-group, double-blind, randomized, placebo-controlled trial of oral cyclophosphamide for treatment of SSc-associated interstitial lung disease were evaluated. Pearson's univariate correlations were determined between the Short Form 36 (SF-36) physical component summary (PCS) and mental component summary (MCS) scales, functional questionnaires, and physiologic parameters of breathing (forced vital capacity [FVC] and single-breath diffusing capacity for carbon monoxide [DLCO]). Student's t-test was used to compare subgroups. Scores from 2 instruments for self-assessment of breathlessness, Mahler's baseline dyspnea index (BDI) and a visual analog scale (VAS) for breathing, were divided at the median. Values for the DLCO and FVC (% predicted) were divided based on the American Thoracic Society guidelines for mild (>70% of predicted), moderate (50-70% of predicted), and severe (

AB - Objective. To determine whether baseline self-assessment measures of health status and physiologic indices of disease severity in alveolitis-positive patients with systemic sclerosis (SSc) correlate with the severity of their dyspnea, and to quantify functional impairment in patients with scleroderma lung disease and compare it with that in patients with chronic obstructive pulmonary disease (COPD). Methods. SSc patients (n = 138) with diffuse (n = 81) or limited (n = 57) cutaneous disease and active alveolitis (determined by bronchoalveolar lavage and/or high-resolution computed tomography) who participated in the National Heart, Lung, and Blood Institute-sponsored, multicenter, parallel-group, double-blind, randomized, placebo-controlled trial of oral cyclophosphamide for treatment of SSc-associated interstitial lung disease were evaluated. Pearson's univariate correlations were determined between the Short Form 36 (SF-36) physical component summary (PCS) and mental component summary (MCS) scales, functional questionnaires, and physiologic parameters of breathing (forced vital capacity [FVC] and single-breath diffusing capacity for carbon monoxide [DLCO]). Student's t-test was used to compare subgroups. Scores from 2 instruments for self-assessment of breathlessness, Mahler's baseline dyspnea index (BDI) and a visual analog scale (VAS) for breathing, were divided at the median. Values for the DLCO and FVC (% predicted) were divided based on the American Thoracic Society guidelines for mild (>70% of predicted), moderate (50-70% of predicted), and severe (

UR - http://www.scopus.com/inward/record.url?scp=13444252280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444252280&partnerID=8YFLogxK

U2 - 10.1002/art.20787

DO - 10.1002/art.20787

M3 - Article

C2 - 15692967

AN - SCOPUS:13444252280

VL - 52

SP - 592

EP - 600

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 2

ER -